Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Safety of retroviral gene marking with a truncated NGF receptor

Open access
Bonini, C., Grez, M., Traversari, C., Ciceri, F., Marktel, S., Ferrari, G., Dinauer, M., Sadat, M., Aiuti, A., Deola, S., Radrizzani, M., Hagenbeek, A., Apperley, J., Ebeling, S., Martens, A., Kolb, H.J., Weber, M., Lotti, F., Grande, A., Weissinger, E., Bueren, J.A., Lamana, M., Falkenburg, J.H.F., Heemskerk, M.H.M., Austin, T., Kornblau, S., Marini, F., Benati, C., Magnani, Z., Cazzaniga, S., Toma, S., Gallo-Stampino, C., Introna, M., Slavin, S., Greenberg, P.D., Bregni, M., Mavilio, F., Bordignon, C.·2003·Nature Medicine

Abstract

To the editor—Random integration into the host cell genome and inappropriate transgene expression are major safety concerns for the clinical use of retroviral vectors. Li et al. recently reported a leukemic transformation of mouse bone marrow cells caused by integration of a transgene-carrying retroviral vector into the Evi1 proto-oncogene. They suggested that expression of the transgene, a truncated form of the p75 low-affinity nerve growth factor receptor (∆LNGFR) with most of the intracytoplasmic tail deleted (from residue 248), contributed to the leukemic progression. Because ∆LNGFR is used as a surface marker in gene therapy clinical trials aimed at controlling graft-versus-host disease (GVHD) after bone marrow transplantation (BMT), a critical assessment of the potential risks associated with the use of such a molecule is essential. In a collaborative effort between 17 independent groups of investigators, we have accumulated both pre-clinical and clinical evidence supporting the safety of ∆LNGFR as a cell-marking molecule. Cumulative data obtained from >300 mice transplanted with bone marrow cells transduced with ∆LNGFR-expressing retroviral vectors showed normal engraftment, persistence and differentiation of ∆LNGFR-expressing hematopoietic stemprogenitor cells (HSCs) in primary, secondary and tertiary BMT recipients, with no adverse events (Table 1 and Supplementary Information online). Over 100 of these mice were monitored for >20 weeks after BMT; more than 70 animals, including 16 recipients of secondary or tertiary BMT, were monitored for >28 weeks. Considering that a total of >1 × 10 transduced cells were transplanted, and assuming an average of one retroviral integration per cell, we estimate the risk of oncogenic transformation after transduction with a ∆LNGFR-encoding retroviral vector to be <1 in 10 integration events. Therefore, expression of ∆LNGFR could not have increased the expected frequency of an insertional oncogenesis event, which has been previously estimated at 10 to 10 per insertion event. Expression of ∆LNGFR did not alter the function or survival of T lymphocytes derived from peripheral blood mononuclear cells transduced with a variety of vectors and studied in different animal models. In pre-clinical models of post-BMT GVHD, no difference in the ability to induce donor chimerism or to mediate GVHD was observed for ∆LNGFR-expressing T cells, as compared with control T cells, in 356 mice, 200 rats and 3 dogs (Table 1 and Supplementary Information online), again with no adverse events. Analysis of 102 independent transductions of human peripheral lymphocytes with two different vectors (SFCMM-3 and SFCM) encoding the same ∆LNGFR detected no change in the expression of markers of lineage, activation or adhesion, or in the proliferative capacity of T cells, as assayed by limiting dilution after polyclonal in vitro stimulation. All cells remained strictly dependent on interleukin-2 for growth and survival, and the Safety of retroviral gene marking with a truncated NGF receptor

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm0403-367

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 177

Metadata

Authors
Bonini, C., Grez, M., Traversari, C., Ciceri, F., Marktel, S., Ferrari, G., Dinauer, M., Sadat, M., Aiuti, A., Deola, S., Radrizzani, M., Hagenbeek, A., Apperley, J., Ebeling, S., Martens, A., Kolb, H. J., Weber, M., Lotti, F., Grande, A., Weissinger, E., Bueren, J. A., Lamana, M., Falkenburg, J. H. F., Heemskerk, M. H. M., Austin, T., Kornblau, S., Marini, F., Benati, C., Magnani, Z., Cazzaniga, S., Toma, S., Gallo-Stampino, C., Introna, M., Slavin, S., Greenberg, P. D., Bregni, M., Mavilio, F., & Bordignon, C.
Venue
Nature Medicine
Published
2003-04
Volume
9
Issue
4
Pages
367-369
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2033149742
Cited by
177
References
1
FWCI
8.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.